

Christopher J Gamper

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7301839/publications.pdf>

Version: 2024-02-01

34
papers

1,327
citations

567144

15
h-index

552653

26
g-index

34
all docs

34
docs citations

34
times ranked

2341
citing authors

#	ARTICLE	IF	CITATIONS
1	HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. <i>Blood</i> , 2012, 120, 4285-4291.	0.6	387
2	Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial. <i>Lancet Haematology</i> , 2019, 6, e183-e193.	2.2	111
3	De novo DNA methylation by DNA methyltransferase 3a controls early effector CD8 ⁺ T-cell fate decisions following activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 10631-10636.	3.3	107
4	Identification of DNA Methyltransferase 3a as a T Cell Receptor-Induced Regulator of Th1 and Th2 Differentiation. <i>Journal of Immunology</i> , 2009, 183, 2267-2276.	0.4	93
5	Cyclophosphamide improves engraftment in patients with SCD and severe organ damage who undergo haploidentical PBSCT. <i>Blood Advances</i> , 2017, 1, 652-661.	2.5	84
6	De Novo DNA Methylation Is Required to Restrict T Helper Lineage Plasticity. <i>Journal of Biological Chemistry</i> , 2012, 287, 22900-22909.	1.6	73
7	Alternative-Donor Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide for Nonmalignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 895-901.	2.0	64
8	Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 325-332.	2.0	61
9	Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults. <i>Blood Advances</i> , 2020, 4, 3913-3925.	2.5	52
10	All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells. <i>Frontiers in Immunology</i> , 2012, 3, 312.	2.2	43
11	mTORC1 Promotes T-bet Phosphorylation To Regulate Th1 Differentiation. <i>Journal of Immunology</i> , 2017, 198, 3939-3948.	0.4	39
12	Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 112-118.	2.0	37
13	Hoyeraal-Hreidarsson Syndrome due to PARN Mutations: Fourteen Years of Follow-Up. <i>Pediatric Neurology</i> , 2016, 56, 62-68.e1.	1.0	29
14	Successful Treatment of Recurrent Autoimmune Cytopenias in the Context of Sinus Histiocytosis With Massive Lymphadenopathy Using Sirolimus. <i>Pediatric Blood and Cancer</i> , 2016, 63, 358-360.	0.8	18
15	Factors Predictive of Relapse of Acute Leukemia in Children after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1033-1039.	2.0	17
16	Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2127-2136.	2.0	17
17	Dnmt3a deletion cooperates with the Flt3/ITD mutation to drive leukemogenesis in a murine model. <i>Oncotarget</i> , 2016, 7, 69124-69135.	0.8	15
18	Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA). <i>Blood</i> , 2015, 126, 2031-2031.	0.6	14

#	ARTICLE	IF	CITATIONS
19	Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4205-4205.	0.6	14
20	Expression and function of TRAF-3 splice-variant isoforms in human lymphoma cell lines. <i>Human Immunology</i> , 2001, 62, 1167-1177.	1.2	11
21	High-dose Cyclophosphamide is Effective Therapy for Pediatric Severe Aplastic Anemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2016, 38, 627-635.	0.3	11
22	Feasibility of Treating Post-Transplantation Minimal Residual Disease in Children with Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1000-1007.	2.0	9
23	Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> . 2015, 21, S29.	2.0	9
24	Genetic and biochemical regulation of CD4 T cell effector differentiation: insights from examination of T cell clonal anergy. <i>Immunologic Research</i> , 2010, 47, 162-171.	1.3	5
25	Donor T cell DNMT3a regulates alloreactivity in mouse models of hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	4
26	Trainee-led Engagement of the Care Team Improves Application of an Institutional Blood Culture Clinical Decision Algorithm to Pediatric Oncology Inpatients: A Single-institution Quality Improvement Project. <i>Pediatric Quality & Safety</i> , 2022, 7, e545.	0.4	2
27	Dnmt3a Deletion Cooperates with the Flt3-ITD Mutation to Drive Leukemogenesis in a Murine Model. <i>Blood</i> , 2014, 124, 3568-3568.	0.6	1
28	Lymphadenopathy as the primary manifestation of malignant transformation in two patients with severe congenital neutropenia. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1072-1075.	0.8	0
29	Outcomes of Children with Hematologic Malignancies Who Relapse After Allogeneic Hematopoietic Cell Transplantation (AlloHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S306.	2.0	0
30	CNS Disease at Diagnosis May Predict Relapse of Hematologic Malignancies in Pediatric Patients After Allogeneic Hematopoietic Cell Transplantation (AlloHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S255-S256.	2.0	0
31	Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Pediatric Patients with High Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S165-S166.	2.0	0
32	Successful Reduced Intensity Alternative Donor Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide for Non-Malignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S101-S102.	2.0	0
33	Factors Predictive of Relapse of Hematologic Malignancies in Pediatric Patients Post Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2012, 120, 4206-4206.	0.6	0
34	Mammalian Target of Rapamycin (mTOR). , 2014, , 703-711.		0